Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Clinical trial NCT03709706 · TERMINATED
Trial details
- NCT number
- NCT03709706
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-31
- Primary completion
- 2022-06-27
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.